UNITED STATES
**SECURITIES AND EXCHANGE COMMISSION**
**Washington, D.C. 20549**

# FORM 8-K

**CURRENT REPORT**
**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): March 26, 2021

# BioCryst Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

| **Delaware** | **000-23186** | **62-1413174** |
|---|---|---|
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |

**4505 Emperor Blvd., Suite 200**
**Durham**, **North Carolina 27703**
(Address of Principal Executive Offices) (Zip Code)

**(919) 859-1302**
(Registrant's telephone number, including area code)

_____
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| **Common Stock** | **BCRX** | **Nasdaq Global Select Market** |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 7.01. Regulation FD Disclosure.**

Following BioCryst Pharmaceuticals, Inc.'s (the "Company") recent announcement of data from an ongoing dose-ranging trial of the Company's oral Factor D inhibitor, BCX9930, in treatment-naïve (no prior treatment with C5 inhibitors) paroxysmal nocturnal hemoglobinuria (PNH) patients, and in PNH patients with an inadequate response to C5 inhibitors, the Company has received questions from investors regarding the treatment-emergent adverse events of hemolysis which occurred in 2 of 16 patients.

One adverse event of hemolysis was reported in a C5-inhibitor naïve patient, with no cause identified. The other adverse event of hemolysis was reported in a C5-inhibitor inadequate response patient, associated with COVID-19 vaccination. In both patients, BCX9930 was continued without changes to dosing, and both patients remain on study.

The information in this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 26, 2021

**BioCryst Pharmaceuticals, Inc.**

By: /s/ Alane Barnes
Alane Barnes
Senior Vice President and Chief Legal Officer